The novelty revealed in our study is that B1 and B2 receptors activated by nonapeptides, LDBK, and BK induce migration and invasion in breast cancer cells via a mechanism that involves the FAK–Src axis, and the antagonism of both receptors in vivo inhibits breast tumor growth. The gene discussed is SRC; the disease is breast cancer.